Follow-up of children exposed to perinatal antiretrovirals

Teratology

Volumn 61, Issue 5, 2000, Pages 395-396

  Fowler, Mary Glenn ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

CONFERENCE PAPER; FETUS DISEASE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL;

ANEMIA; ANTI-HIV AGENTS; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034016981     PISSN: 00403709     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9926(200005)61:5<395::AID-TERA15>3.0.CO;2-H     Document Type: Conference Paper

References (9)

1. Ayers KM, Torrey CE, Reynolds DJ. 1997. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundam Appl Toxicol 38:195-198.
2. Beckerman KP, Morris AB, Stek A. 2000. Mode of delivery and risk of vertical transmission of HIV-1 [letter]. N Engl J Med 341:205-206.
3. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguerre I, Rotig A, Mayaux MJ, Delfraissy JF. 1999. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354:1084-1089.
4. Connor EM, Sperling RS, Gelber R, Kiseley P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Sherer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J, Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 1994. Reduction of materno-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331:1173-1180.
5. Culnane M, Fowler MG, Lee S, McSherry G, Brady M, O'Donnell K, Mofenson L, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B, Oleske J, Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. 1999. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 281:151-157.
6. Hanson IC, Antonelli TR, Sperling RS, Oleske JM, Cooper E, Culnane M, Fowler MG, Kalish LA, Lee SS, McSherry G, Mofenson L, Shapiro DE. 1999. Lack of tumors in infants with perinatal HIV type 1 exposure and fetal/neonatal exposure to zidovudine. J AIDS 20:463-467.
7. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, Irion O, Kaiser L., Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. 1998. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 12:F241-F247.
8. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC. 1997. Transplacental effects of 3′-azido-2′,3′dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 89:1602-1608.
9. Smith ME, and the US Nucleoside Safety Review Working Group. Ongoing nucleoside safety review of HIV-exposed children in US studies. Second conference on global strategies for the prevention of HIV transmission from mothers to infants. Sept. 4, 1999, Montreal (#096).